France· FR:60051647
SOGROYA 10 mg/1,5 ml, solution injectable en stylo prérempli
A somapacitan product containing somapacitan, registered in France by NOVO NORDISK (DANEMARK), on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Somapacitan is registered in 13 of 19 countries.
Countries holding a registration under ATC H01AC07 (somapacitan), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Somapacitan · ATC H01AC07
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- SOMAPACITAN
- Manufacturer
- NOVO NORDISK (DANEMARK)
- Country
- France (FR)
- ATC code
- H01AC07
- ATC class
- Somapacitan
- Defined daily dose
- 0.6 mg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302472971 stylo prérempli multidose(s) de 1 cartouche en verreEUR 402.97
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
303 interactions on record for somapacitan.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Somapacitan · interactions on record
303 records
- 2 severe
- 296 moderate
- 5 minor
Most severe, free to view
- OmeprazoleA02BC01moderate
- PantoprazoleA02BC02moderate
- LansoprazoleA02BC03moderate
- RabeprazoleA02BC04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Somapacitan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandSogroya 10 mg/1.5 mL solution for injection in pre-filled penNovo Nordisk A/S
- NetherlandsSogroya 10 mg/1,5 ml, oplossing voor injectie in een voorgevulde penNovo Nordisk A.S.
- CzechiaSOGROYANovo Nordisk A/S, Bagsvaerd
- CanadaSOGROYANOVO NORDISK CANADA INC
- SwitzerlandSogroya 10 mg/ 1.5 ml, Injektionslösung im FertigpenNovo Nordisk Pharma AG
- SpainSOGROYA 10 MG/1,5 ML SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- FinlandSogroyaNovo Nordisk A/S
- BelgiumSogroya 10 mg/1.5 mlNovo Nordisk
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Sogroya
- Norway · Sogroya
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/331ba5e5-7f24-48c7-b620-0cfbbab438af GET /v1/drugs/331ba5e5-7f24-48c7-b620-0cfbbab438af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60051647",
"date_amm": "2021-03-31",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/20/1501",
"substance": "SOMAPACITAN",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about somapacitan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.